Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy
This year’s ESMO congress will present new late-breaking data for doublet immune therapy for patients with localized renal cell carcinoma. This may give hope to extending the time patients live without recurrence.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
